Overview

Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminopterin in treating patients who have refractory or recurrent endometrial cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
Aminopterin